EGM
MRNA icon

Encore Global Management’s Moderna MRNA Stock Holding History

Encore Global Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70K Hold
1,000
– – 0.07% 53
2026
Q1 		$50.8K Buy
+1,000
New +$46.7K 0.04% 70

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Encore Global Management's MRNA Position: Q2 2026 in Review

Encore Global Management held its Moderna (MRNA) position steady in Q2 2026 at 1,000 shares worth $70K. The position accounts for 0.07% of the portfolio, ranked #53.

Encore Global Management first reported a position in MRNA in Q1 2026 and has held it in 2 quarters since. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Encore Global Management held 1,000 shares of Moderna worth $70K as of Q2 2026.
  • Encore Global Management left its Moderna share count unchanged in Q2 2026.
  • Moderna made up 0.07% of Encore Global Management's portfolio in Q2 2026, its #53 holding.
  • Encore Global Management first reported a position in Moderna in Q1 2026 and has held it in 2 quarters since.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Encore Global Management's 13F filing for Q2 2026, filed 11 Aug 2026.